Vaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average – What’s Next?

Vaxart, Inc. (NASDAQ:VXRT)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.73 and traded as low as $0.59. Vaxart shares last traded at $0.62, with a volume of 1,568,544 shares changing hands.

Vaxart Stock Performance

The stock has a 50 day moving average of $0.68 and a 200 day moving average of $0.73. The stock has a market capitalization of $140.95 million, a P/E ratio of -1.51 and a beta of 0.62.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mesirow Financial Investment Management Inc. boosted its position in shares of Vaxart by 100.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after buying an additional 20,000 shares during the period. XTX Topco Ltd raised its stake in Vaxart by 869.3% during the 3rd quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 122,387 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Vaxart during the 2nd quarter worth $402,000. Geode Capital Management LLC grew its stake in shares of Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after purchasing an additional 346,725 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after purchasing an additional 2,095,274 shares during the period. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.